$OVID
Ovid Therapeutics Inc.

2019 Q1 Form 10-Q Financial Statement

#000156459019016562 Filed on May 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.700M $5.000M
YoY Change -6.0% 67.91%
% of Gross Profit
Research & Development $9.337M $8.475M
YoY Change 10.18% -72.91%
% of Gross Profit
Depreciation & Amortization $76.54K $26.37K
YoY Change 190.21% 42.84%
% of Gross Profit
Operating Expenses $14.05M $13.43M
YoY Change 4.64% -60.8%
Operating Profit -$14.05M -$13.43M
YoY Change 4.64% -60.8%
Interest Expense $300.0K $200.0K
YoY Change 50.0%
% of Operating Profit
Other Income/Expense, Net $253.3K $247.0K
YoY Change 2.57% 973.91%
Pretax Income -$13.80M -$13.20M
YoY Change 4.55% -61.45%
Income Tax
% Of Pretax Income
Net Earnings -$13.80M -$13.18M
YoY Change 4.68% -61.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$455.4K -$536.6K
COMMON SHARES
Basic Shares Outstanding 38.65M 24.62M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.64M $74.16M
YoY Change -19.58% 67.78%
Cash & Equivalents $54.60M $29.20M
Short-Term Investments $5.041M $44.96M
Other Short-Term Assets $1.900M $1.500M
YoY Change 26.67% -34.78%
Inventory
Prepaid Expenses
Receivables $1.300M
Other Receivables $0.00
Total Short-Term Assets $62.80M $75.69M
YoY Change -17.03% 62.63%
LONG-TERM ASSETS
Property, Plant & Equipment $66.16K $100.0K
YoY Change -33.84% 114.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $331.1K $2.900M
YoY Change -88.58% 1347.97%
Total Long-Term Assets $3.856M $3.012M
YoY Change 28.02% 354.86%
TOTAL ASSETS
Total Short-Term Assets $62.80M $75.69M
Total Long-Term Assets $3.856M $3.012M
Total Assets $66.66M $78.70M
YoY Change -15.3% 66.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.410M $2.400M
YoY Change 83.77% 51.92%
Accrued Expenses $3.661M $4.200M
YoY Change -12.83% 27.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.072M $6.600M
YoY Change 22.3% 35.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M
YoY Change
Total Long-Term Liabilities $1.300M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.072M $6.600M
Total Long-Term Liabilities $1.300M $0.00
Total Liabilities $9.410M $6.600M
YoY Change 42.57% 34.69%
SHAREHOLDERS EQUITY
Retained Earnings -$166.5M -$113.9M
YoY Change 46.18% 62.37%
Common Stock $223.7M $186.0M
YoY Change 20.28% 1890565.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $57.25M $72.09M
YoY Change
Total Liabilities & Shareholders Equity $66.66M $78.67M
YoY Change -15.27% 66.66%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$13.80M -$13.18M
YoY Change 4.68% -61.5%
Depreciation, Depletion And Amortization $76.54K $26.37K
YoY Change 190.21% 42.84%
Cash From Operating Activities -$12.87M -$12.93M
YoY Change -0.46% 79.53%
INVESTING ACTIVITIES
Capital Expenditures $4.324K $7.581K
YoY Change -42.96% -37.51%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$45.00M
YoY Change -100.0%
Cash From Investing Activities -$8.974K -$45.07M
YoY Change -99.98% 44972.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.91M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.99M 75.40K
YoY Change 40994.71% -115.08%
NET CHANGE
Cash From Operating Activities -12.87M -12.93M
Cash From Investing Activities -8.974K -45.07M
Cash From Financing Activities 30.99M 75.40K
Net Change In Cash 18.11M -57.92M
YoY Change -131.27% 642.6%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$12.93M
Capital Expenditures $4.324K $7.581K
Free Cash Flow -$12.87M -$12.93M
YoY Change -0.49% 79.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5040700
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54600081
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5011034
CY2019Q1 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
1257649
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
600104
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1925080
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2167391
CY2018Q4 us-gaap Assets Current
AssetsCurrent
44268147
CY2019Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
3311527
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2797561
CY2019Q1 us-gaap Security Deposit
SecurityDeposit
123295
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
122155
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66157
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69867
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
331103
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
391872
CY2019Q1 us-gaap Assets
Assets
66655592
CY2018Q4 us-gaap Assets
Assets
47649602
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
24654
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223701228
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191477598
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1794967
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4410421
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13800195
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
253340
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13182758
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3755595
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3661131
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5088862
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1350
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166495473
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
57245801
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66655592
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38693018
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38693018
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9337304
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8071552
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8844457
CY2019Q1 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
1338239
CY2019Q1 us-gaap Liabilities
Liabilities
9409791
CY2018Q4 us-gaap Liabilities
Liabilities
8844457
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
3
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
38693
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1829
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152695278
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38805145
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47649602
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24654114
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24654114
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8474557
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13800195
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4955307
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13182758
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3179
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35914
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13797016
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13218672
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30522028
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1642540
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73104
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3179
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
83436503
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12678
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
62723
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-35914
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
72088199
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1642540
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1794967
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76535
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26372
CY2019Q1 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-26487
CY2018Q1 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
22998
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-242311
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
67246
CY2019Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-1140
CY2018Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-39465
CY2019Q1 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
657545
CY2019Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
513966
CY2018Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
2033699
CY2019Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
264059
CY2018Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
365454
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1430738
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
186965
CY2019Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1338239
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12866387
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12926412
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
45014899
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4324
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7581
CY2019Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
4650
CY2018Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
49550
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8974
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45072030
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30912720
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
73104
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
62723
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12678
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30985824
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75401
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18110463
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-57923041
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87125600
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29202559
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(C) Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2019Q1 ovid Gross Proceeds From Issuance Of Stock
GrossProceedsFromIssuanceOfStock
33000000
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30500000
CY2019Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
54600081
CY2019Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54600081
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5037521
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3179
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36489618
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36489618
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5012863
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1829
CY2019Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
5000000
CY2019Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95852
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
86164
CY2019Q1 us-gaap Depreciation
Depreciation
10000
CY2018Q1 us-gaap Depreciation
Depreciation
9000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
331000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
67000
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2019Q1 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
1807193
CY2018Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
1352133
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1319930
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2779021
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
385594
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
772785
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
148414
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184923
CY2019Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share held
CY2019Q1 ovid Gross Proceeds From Issuance Of Stock
GrossProceedsFromIssuanceOfStock
33000000
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30500000
CY2019Q1 ovid Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates
MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates
0.0999
CY2019Q1 ovid Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders
MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders
0.1499
CY2019Q1 ovid Payment Of Share Issuance Expenses By Persons Owning Ten Percent Or More Of Common Stock
PaymentOfShareIssuanceExpensesByPersonsOwningTenPercentOrMoreOfCommonStock
0
CY2019Q1 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.
CY2019Q1 us-gaap Dividends
Dividends
0
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1642540
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1794967
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4714383
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1458963
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
251723
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5921623
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2780045
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.10
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.07
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.00
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.70
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.99
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M20D
CY2019Q1 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y11M1D
CY2019Q1 ovid Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Expired Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredWeightedAverageRemainingContractualTerm1
P7Y10M28D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153485
CY2019Q1 ovid Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Expired Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrExpiredAggregateIntrinsicValue
108137
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10500000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M19D
CY2019Q1 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-19-016562-index-headers.html Edgar Link pending
0001564590-19-016562-index.html Edgar Link pending
0001564590-19-016562.txt Edgar Link pending
0001564590-19-016562-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ovid-10q_20190331.htm Edgar Link pending
ovid-20190331.xml Edgar Link completed
ovid-20190331.xsd Edgar Link pending
ovid-20190331_cal.xml Edgar Link unprocessable
ovid-20190331_def.xml Edgar Link unprocessable
ovid-20190331_lab.xml Edgar Link unprocessable
ovid-20190331_pre.xml Edgar Link unprocessable
ovid-ex101_221.htm Edgar Link pending
ovid-ex311_8.htm Edgar Link pending
ovid-ex312_7.htm Edgar Link pending
ovid-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending